Fear of change is a key limiting factor that is slowing the adoption and value of AI across life sciences. It doesn't have to ...

Proper legal structuring is essential when it comes to transferring Chinese biotech intellectual property and clinical assets ...

Cuts to federal research funding at universities and research organizations are pushing academic scientists into life ...

Sometimes the key to making a breakthrough in research, in any field, is to look at the problem differently than anybody has ...

BIO was as busy as ever in Boston this year. With more to come soon, here are a few initial thoughts on three events I ...

New IRS requirements for R&D tax credits are coming into effect for tax year 2025. Life sciences companies should prepare for ...

By Rob Wright, Chief Editor, Life Science Leader Follow Me On Twitter @RfwrightLSL. Chris Anzalone. It was the summer of 2007 when Chris Anzalone, Ph.D., got a call from Arrowhead Research Company. At ...

This article is part one of a two-part series. Part two is available here.. Part 1: AI for rapid Drug Discovery. In the rapidly evolving landscape of pharmaceutical development, AI promises to ...

For people living with schizophrenia, the current drug treatment landscape is filled with cracks, crevices, and canyons that prevent a majority of patients from reaching anything close to a normal ...

By Rob Wright, Chief Editor, Life Science Leader Follow Me On Twitter @RfwrightLSL. Matt Patterson “THAT WAS A TERRIFYING MOMENT,” reflects Matt Patterson, cofounder, chairman, and CEO of Audentes ...

FDA Trials And Tribulations With Connect Biopharma's Barry Quart On this week's episode of the Business of Biotech, Barry Quart, CEO of Connect Biopharma, weighs in on the current state of engagement ...

Since clinical trials have become increasingly complex with more data being collected, this consequently puts more pressure on sponsors to improve efficiencies while still maintaining quality.